FDA authorizes Roche automated mass spectrometry platform; FoundationOne Liquid CDx becomes ESR1 companion test; CAR T cells found in gut

A laboratory microscope with binocular eyepieces, a glass slide on its stage holding a softly stained tissue section.

The Food and Drug Administration (FDA) granted De Novo authorization to Roche's cobas pro i 601 mass spectrometry platform with a gabapentin assay, Roche said Nov. 16. The authorization covers up to 22 more assays.

The FDA also authorized FoundationOne Liquid CDx as the companion diagnostic for giredestrant in ESR1-mutated breast cancer, and a Nature Medicine study found CAR T cells in gut tissue of patients with enterocolitis after BCMA-directed therapy.

  • FDA Nov 16, 2026
    The Food and Drug Administration (FDA) granted De Novo authorization for Roche's cobas pro i 601 platform with the Ionify Gabapentin assay, expanding Roche's diagnostic menu into therapeutic drug monitoring, the company said Nov. 16. The authorization includes a predetermined change control plan covering up to 22 more Ionify assays, which Roche said are not yet available. Roche said the system pairs mass spectrometry with an automated, standardized workflow to move the technology from specialized reference facilities to the core laboratory.
    Sources: Roche, CAP Today
  • FDA Nov 16, 2026
    With its Nov. 16 approval of giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, the Food and Drug Administration (FDA) authorized the FoundationOne Liquid CDx assay as a companion diagnostic to identify patients with ESR1 mutations. The indication requires ESR1 mutations detected by an FDA-authorized test. In the ESR1-mutated population of the evERA trial, median progression-free survival was 10 months with giredestrant and everolimus versus 5.5 months with physician's choice of endocrine therapy and everolimus.
    Source: FDA
  • Research Nov 19, 2026
    In the nine of 158 patients who developed immune effector cell-associated enterocolitis after the BCMA-directed CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel), about 5% of those treated, tissue samples showed CAR T cells had accumulated in the digestive tract, where they appeared to drive ongoing inflammation and damage, according to an MD Anderson study published Nov. 19 in Nature Medicine. The corresponding author described the condition as a distinct disorder driven by the therapy, and the team said testing tissue for CAR-positive T cells could speed diagnosis and treatment.
  • Policy Nov 16, 2026
    The Department of Health and Human Services (HHS) Office for Civil Rights issued a final rule Nov. 16 modifying the HIPAA Privacy Rule. It cuts the time to respond to patient requests for record copies from 30 calendar days to 15, Healthcare Dive reported, and establishes a right to receive electronic records through a personal health app, amends access fees and reduces identity verification burdens, according to HHS. It also permits disclosures to social services agencies and community-based organizations. The rule takes effect 60 days after publication, with compliance due 180 days after that, Healio reported.

The weekly innovation roundup for pathology, published every Sunday for the week before; every item links to its sources. Latest pathology news · All specialties

Latest news

Tagged pathology, from the daily briefing

  1. AGA clinical practice update reviews when to use liver biopsy for liver disease, abnormal liver tests and liver masses
  2. High-risk benign breast disease detected at 1.11 per 1,000 screening mammograms in a national consortium study
  3. National Kidney Foundation workshop says measuring urine albumin is generally preferred over total urine protein

See all the latest news